Posted by Michael Wonder on 11 Apr 2022
Alzheimer's drug makers seek accelerated FDA review despite U.S. coverage decision
8 April 2022 - Eisai and Eli Lilly on Friday said they still plan to seek accelerated U.S. approval for experimental Alzheimer's drugs even after the Medicare health plan decided to severely limit coverage of medicines approved in that manner.
On Thursday, after a month's long review and a pressure campaign from patient advocacy groups, CMS) said it would only pay for Biogen's Aduhelm, and other drugs that work in a similar fashion, for patients enrolled in valid clinical studies, unless the treatments demonstrate clear evidence of patient benefit.
